Stem cell retinal cells implanted in one eye for retinitis pigmentosa
Tests implanted stem cell-derived retinal cells in adults with inherited retinitis pigmentosa.
Key facts
- Who runs it
- Centre D'Etude Des Cellules Souches
- Where
- Paris, FranceSee the site
- Registry title
- Tissue replacement in RPE related dystrophies
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 12 people, planned
- Started
- 19 Aug 2019
- Expected to end
- 2 Jun 2027
- Type of study
- Interventional
- Record updated
- 2 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with retinitis pigmentosa caused by a single confirmed gene change in RPE65, LRAT or MerTK. It tests the safety of an implant of stem-cell-derived cells placed in one eye.
- Age
- 18 to 64 years (the record also states 65 years as the upper limit in the criteria).
- Sex
- All sexes can join.
- Disease stage
- First group: visual acuity of 20/200 or worse in the better eye (legally blind). Second group: visual acuity between 20/63 and 20/800 in the worse eye, visual field beyond 10° central to the V4 test, and a visible photoreceptor outer nuclear layer on an OCT scan.
- Earlier treatment
- People who had a gene or cell therapy product, or Luxturna®, cannot join. No systemic corticosteroid, immunosuppressive, immunomodulating or anti-retroviral drugs within 2 months before baseline.
- Biomarker or test result
- A genetic test confirming a single-gene mutation in RPE65, LRAT or MerTK. During the SARS-Cov-2 pandemic, a negative SARS-CoV-2 test.
Main reasons for not taking part
- Allergy or sensitivity to a product used in the study
- Earlier gene or cell therapy, or treatment with Luxturna®
- Pre-formed anti-HLA antibodies against the hESC line RC9 with MFI above 2000, or in the middle range (500 to 2000) with a significant medical history
- Another eye disease or clouding of the eye that prevents accurate assessment
- Systemic corticosteroid or immune-affecting drugs within 2 months before baseline
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Documented diagnosis of retinis pigmentosa based on a genetic test confirming the presence of a monogenic mutation that affects a gene involved in the visual signalling process specifically at the level of RPEs, namely RPE65 or LRAT, or MerTK
- 18 years old ≤ Age ≤ 65 years old
- During the SARS-Cov-2 pandemic period, patient negative to SARS-CoV-2 (PCR or any new test validated)
- For patient of the first cohort: Visual acuity ≤ 20/200 in the best eye (legally blind). For patient of the second cohort: 20/63 > Visual acuity > 20/800 in the worst eye And Visual field exceeding 10° central to the V4 test in the worst eye And Visible photoreceptor outer nuclear layer (ONL) on a spectral domain optical coherence tomography (OCT) scan
Who cannot take part
- Prior treatment with a gene or cell therapy product
- Patients treated with Luxturna®
- Systemic corticosteroid therapy or other immunosuppressive/ immunomodulating or anti-retroviral drugs within 2 months prior to baseline
- History of allergy or sensitivity to one of the products used during the study
- Patients with preformed anti-HLA antibodies against the human Embryonic Stem Cell (hESC) line RC9 with MFI > 2000 or patients with intermediate MFI values (between 500 and 2000) at screening associated to medical history of clinical significance, according to expert’s opinion
- Presence of any ocular disease or ocular media opacity which in the opinion of the investigator precludes accurate evaluation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in France
- Quinze-Vingts National Ophthalmology HospitalParis, FranceTaking people
About the trial
What the trial wants to find out
To assess safety and tolerability of implantation of the IMP (ISTEM-01) in patients with retinitis pigmentosa over 56 weeks after IMP implantation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A phase 1/2, open-label, safety, tolerability and preliminary efficacy study of implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)) in patients with retinitis pigmentosa due to monogenic mutation
- Plain-language title
- Stem cell retinal cells implanted in one eye for retinitis pigmentosaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-513662-18-00, who can take part
- Record updated
- 2 April 2025